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444–53.ReplyWe read with interest the comments on our study (1) by Dr. Ghali.
Dr. Ghali felt we did not emphasize the differences in baseline
characteristics between patients on metoprolol and carvedilol.
Because our study was not a randomized trial to evaluate a com-
parison between metoprolol and carvedilol, we carried out a fully
adjusted multivariate Cox regression model and an additional
propensity scored-adjusted analysis. As we explained in the article,
we adjusted the multivariate model for baseline characteristics that
had a signiﬁcant impact on the endpoint of hospitalization for heart
failure or death (Table 2 in our article). This approach does not
eliminate unmeasured confounding, as we pointed out in the limi-
tations section. Therefore, the differences in the baseline character-
istics between patients on metoprolol and carvedilol as mentioned by
Dr. Ghali are taken into account in our analysis.
Dr. Ghali felt that the 12% of patients on metoprolol tartrate
should be excluded from the analysis since it has not been docu-
mented to reduce survival or hospitalization in a randomized trial.
Because some of the patients changed from tartrate to succinate (or
to carvedilol or came off the drug) throughout the study we wanted
to include and keep these patients in the analysis. Because we used
time-dependent analysis, thus always taking into account the risk
time the patient was on a particular beta-blocker with a speciﬁc
dose, we kept these patients in the analysis. If we exclude the
patients on metoprolol tartrate at baseline, the results on the
endpoint of heart failure or death were, however, similar and re-
mained statistically signiﬁcant.Regarding question 3, we used time-dependent analysis. This
means that throughout follow-up, we are taking into account the risk
time the patient is on a speciﬁc drug (at a speciﬁc dose) and its
contribution to the overall risk of the endpoint. Thus, if a patient
decided to go off the drug or change frommetoprolol to carvedilol or
the opposite, the risk time contributed on either drug is taken into
account in the analysis. Therefore, we think it wouldwrong to exclude
these patients from the analysis. We do not have precise information
on the cause of why patients changed type of beta-blocker.
Finally, we believe that the synergistic effect seen in patients
treated with carvedilol who had a left bundle branch block may be
related to favorable reverse remodeling associated with the use of
resynchronization therapy in combination with carvedilol.*Martin H. Ruwald, MD
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